J&J Device Businesses Return To Growth Led By Electrophysiology And Surgery
The health care giant’s medical device revenues grew 8.8% in the first quarter, reflecting the recovery of interventions and surgeries since the start of the pandemic.
You may also be interested in...
Among the company's many milestones in the first quarter, the FDA approved its Therasphere radiation seed device, a major building block of the company's interventional oncology business.
Recovering pharmaceutical and medical device revenues at J&J hint at the green shoots germinating from the pandemic. Roche’s COVID-19 diagnostics revenue growth was its own green shoot, but can these be maintained as the pandemic evolves?
Inivata will remain a separate liquid biopsy division alongside NeoGenomics’ growing clinical, pharma and informatics divisions.